Google
KARD Stock Price & Analysis — Kardigan, Inc. Common Stock (Healthcare >> Biotechnology)
KARD FAQ
What is KARD's ROE?
Kardigan, Inc. Common Stock reports a Return on Equity (ROE) of 24.65%.
What is KARD's dividend yield?
Kardigan, Inc. Common Stock offers a dividend yield of 0.00%.
What is KARD's Quality Score?
Our AI rates KARD's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KARD?
Our AI Timing Score for KARD is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KARD belong to?
Kardigan, Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
KARD AI Analysis Summary
Our AI summary for KARD: Kardigan, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 24.65%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 19.97
Price
-0.85
(-4.08%)
Day Change
|
|
|---|
KARD, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 19.97 |
| PBV / Sector |
-6.19 / 44,219.29
|
| Earning Per Share | -0.80 |
| PE / Sector |
N/A / 19.28
|
| PEG or PE/Growth / Sector |
N/A / 1.23
|
| Average 1M Daily Value |
6.20 M
|
| Average 1W Daily Value |
3.85 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:45 |
| Symbol | KARD |
| Name | KARDIGAN, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 89.34 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,860.04 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 506 Carnegie Center Drive, Princeton, NJ, United States, 08540
Phone: (415) 573-3220
Website: https://www.kardigan.bio
Employees: 241
Sector: Healthcare >> Biotechnology
Description: Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap